See the DrugPatentWatch profile for qulipta
Qulipta, also known by its generic name atogepant, is a medication approved for the preventive treatment of migraine [1]. It is a calcitonin gene-related peptide (CGRP) receptor antagonist, a class of drugs designed to target a pathway involved in migraine attacks [2][3]. Clinical trials have demonstrated its efficacy in reducing the number of monthly migraine days for adults [1][4].
How effective is Qulipta in reducing migraine days?
In clinical studies, Qulipta has shown a statistically significant reduction in monthly migraine days compared to placebo. For instance, in a pivotal Phase 3 trial, patients taking 60 mg of Qulipta once daily experienced an average reduction of 4.2 migraine days per month after 12 weeks, compared to a reduction of 1.9 days in the placebo group [4]. Another study reported an average reduction of 3.7 migraine days for patients taking 10 mg of Qulipta daily [4]. The drug's effectiveness is generally assessed by the change in the mean number of monthly migraine days from baseline to the treatment period [4].
What are the common side effects of Qulipta?
The most frequently reported side effects of Qulipta include nausea, constipation, diarrhea, and fatigue [1]. These adverse events are generally mild to moderate in severity [4].
How does Qulipta work to prevent migraines?
Qulipta works by blocking the action of calcitonin gene-related peptide (CGRP) [2]. CGRP is a molecule that is thought to play a role in the pathophysiology of migraine [2][3]. By inhibiting CGRP, Qulipta is believed to reduce the inflammatory and vasodilatory processes that contribute to migraine pain and other symptoms [2].
When was Qulipta approved and by whom?
Qulipta was approved by the U.S. Food and Drug Administration (FDA) on September 27, 2021 [1]. It is manufactured by AbbVie [5].
What is the typical dosage for Qulipta?
The recommended dosage of Qulipta for the preventive treatment of migraine is 60 mg taken orally once daily [1]. Patients can take it with or without food [1].
Are there any alternatives to Qulipta for migraine prevention?
Yes, there are several other medications approved for migraine prevention, including other CGRP inhibitors (both oral and injectable), as well as older drug classes like beta-blockers, antidepressants, and anti-seizure medications [2][6]. The choice of treatment often depends on individual patient needs, medical history, and response to previous therapies [6].
What is the patent status for Qulipta?
Information regarding the specific patent status of Qulipta can be found on DrugPatentWatch.com [7]. This resource provides details on patents that cover the drug, which are crucial for understanding market exclusivity and the potential for generic competition [7].